Related Experiment Video
Updated: Jun 6, 2026
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
LAG-3 in Cancer Immunotherapy
Monica V Goldberg1, Charles G Drake
1Johns Hopkins Kimmel Cancer Center, 1650 Orleans Street - CRB 423, Baltimore, MD 21231, USA.
Current Topics in Microbiology and Immunology
|November 19, 2010
Summary
Lymphocyte-activation gene 3 (LAG-3) is a molecule on immune cells involved in T cell exhaustion. Blocking LAG-3 interactions shows promise in cancer immunotherapy clinical trials.
Area of Science:
- Immunology
- Cancer Biology
- Molecular Biology
Background:
- Lymphocyte-activation gene 3 (LAG-3) is a cell surface molecule found on activated T cells, NK cells, B cells, and dendritic cells.
- LAG-3 plays a role in immune cell function, with its interaction with Class II MHC modulating dendritic cell activity.
- Recent studies highlight LAG-3's involvement in CD8 T cell exhaustion.
Purpose of the Study:
- To review the structural and functional biology of LAG-3.
- To examine preclinical and clinical data on LAG-3's role in cancer immunotherapy.
Main Methods:
- Literature review of existing preclinical and clinical studies.
- Analysis of the structural and functional aspects of LAG-3.
- Evaluation of data on LAG-3 blockade in cancer treatment.
Main Results:
- LAG-3 is expressed on various immune cells and influences their function.
- The LAG-3/Class II MHC interaction impacts dendritic cell function.
- LAG-3 blockade is under investigation in clinical trials for cancer patients.
Conclusions:
- LAG-3 is a significant factor in immune responses and T cell exhaustion.
- Targeting the LAG-3 pathway represents a potential strategy for cancer immunotherapy.
